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Background: Human immunodeficiency virus type 1 (HIV-1) subtype C (C-HIV) is spreading rapidly and is now
responsible for >50% of HIV-1 infections worldwide, and >95% of infections in southern Africa and central Asia.
These regions are burdened with the overwhelming majority of HIV-1 infections, yet we know very little about the
pathogenesis of C-HIV. In addition to CCR5 and CXCR4, the HIV-1 envelope glycoproteins (Env) may engage a
variety of alternative coreceptors for entry into transfected cells. Whilst alternative coreceptors do not appear to
have a broad role in mediating the entry of HIV-1 into primary cells, characterizing patterns of alternative
coreceptor usage in vitro can provide valuable insights into mechanisms of Env-coreceptor engagement that may
be important for HIV-1 pathogenesis.
Results: Here, we characterized the ability of luciferase reporter viruses pseudotyped with HIV-1 Envs (n = 300)
cloned sequentially from plasma of 21 antiretroviral therapy (ART)-naïve subjects experiencing progression from
chronic to advanced C-HIV infection over an approximately 3-year period, who either exclusively maintained CCR5-
using (R5) variants (n = 20 subjects) or who experienced a coreceptor switch to CXCR4-using (X4) variants (n = 1
subject), to utilize alternative coreceptors for entry. At a population level, CCR5 usage by R5 C-HIV Envs was strongly
linked to usage of FPRL1, CCR3 and CCR8 as alternative coreceptors, with the linkages to FPRL1 and CCR3 usage
becoming statistically more robust as infection progressed from chronic to advanced stages of disease. In contrast,
acquisition of an X4 Env phenotype at advanced infection was accompanied by a dramatic loss of FPRL1 usage.
Env mutagenesis studies confirmed a direct link between CCR5 and FPRL1 usage, and showed that the V3 loop
crown, but not other V3 determinants of CCR5-specificity, was the principal Env determinant governing the ability
of R5 C-HIV Envs from one particular subject to engage FPRL1.
Conclusions: Our results suggest that, in the absence of coreceptor switching, the ability of R5 C-HIV viruses to
engage certain alternative coreceptors in vitro, in particular FPRL1, may reflect an altered use of CCR5 that is
selected for during progressive C-HIV infection, and which may contribute to C-HIV pathogenicity.
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Entry of human immunodeficiency virus type 1 (HIV-1)
into cells involves the interaction of the viral gp120 enve-
lope glycoproteins (Env) with cellular CD4 and a second-
ary coreceptor, which is typically one of the chemokine
receptors CCR5 or CXCR4 [1]. HIV-1 Envs are phenotyp-
ically characterized by their ability to use CCR5 (R5),
CXCR4 (X4) or both coreceptors (R5X4) for entry. In
addition to CCR5 and CXCR4, alternative coreceptors
such as CCR1, CCR2, CCR3, CCR8, CX3CR1, CXCR6,
FPRL1, GPR1, GPR15, APJ, STRL33 and D6 can act as
lentiviral coreceptors and mediate the entry of certain
HIV-1, HIV-2 and simian immunodeficiency virus (SIV)
strains into transfected cell lines [2-5].
Whilst alternative coreceptors do not appear to have a
broad role in mediating the entry of HIV-1 into primary
cells, a recent report described acute HIV-1 infection
with a variant that could not use CCR5 or CXCR4, and
used only GPR15 efficiently [6], suggesting a larger po-
tential role for alternative coreceptors than currently
recognized. SIV strains do not use CXCR4, but exhibit
alternative coreceptor usage that is typically broader and
more efficient than HIV-1 subtype B (B-HIV) [2,7]. HIV-
1 subtype C strains (C-HIV) also rarely use CXCR4, al-
though CXCR4 usage may be more common than previ-
ously appreciated (reviewed in [8,9]), and have been
reported to have relatively efficient in vitro usage of the
alternative coreceptors CCR3, CCR8 and FPRL1 [10,11],
or GPR15, CXCR6 and APJ [12]. Unlike HIV-1, however,
non-pathogenic SIV infection in natural hosts can be
mediated by CXCR6, GPR15 and GPR1 in vivo [13,14].
Similarly, earlier studies showed that red-capped manga-
beys usually lack functional CCR5, and that CCR2 was
commonly used by SIVrcm strains [15]. These studies
suggest an in vivo role for alternative coreceptors in SIV
infection of natural hosts.
R5 HIV-1 viruses are typically associated with HIV-1
transmission and establishment of new infections, and are
dominant in the chronic phase of infection. However, in
up to 40 to 50% of individuals infected with B-HIV, pro-
gression to late stages of infection is associated with a
switch in coreceptor specificity, with emergence of X4 or
R5X4 viral variants [16,17]. The emergence of CXCR4-
using HIV-1 viruses is associated with rapid CD4+ T-cell
decline and progression from chronic to advanced stages
of HIV-1 infection. In contrast, most individuals infected
with C-HIV, which is the most prevalent HIV-1 subtype
worldwide, progress from chronic to advanced stages of
infection whilst exclusively harbouring R5 viruses [8,9,18].
Whether disease progression in the presence of only R5
strains reflects mainly cumulative damage of ongoing rep-
lication, or indicates the emergence of variants with
unique biological features that may contribute to in-
creased pathogenicity is an important question. In supportof the latter possibility, recent studies have shown that
compared to transmitted/founder (T/F) viruses, R5 vi-
ruses from chronic C-HIV infections exhibit a more
flexible recognition of CCR5, as demonstrated by their
ability to interact with an altered conformation of CCR5
induced by the CCR5 antagonist maraviroc (MVC)
[19,20]. In addition, the ability of C-HIV Envs to inter-
act with CCR5 has been shown to correlate with their
ability to use CCR3, CCR8 and FPRL1 as alternative
coreceptors in vitro [10]. Thus, the ability of R5 Envs to
engage certain alternative coreceptors, albeit in cell
lines, may also reflect an altered use of CCR5 that is se-
lected for during progressive C-HIV infection and
which may contribute to C-HIV pathogenicity.
Relatively little is known about the pathogenesis of C-
HIV. This is, in part, because nearly all studies on C-HIV
have been cross-sectional studies of chronically-infected
subjects, studies of early/acute infected individuals, rela-
tively small studies of late stage C-HIV infection where sub-
jects were antiretroviral therapy (ART)-experienced which
likely altered the natural history of the disease, or studies
which relied on primary C-HIV isolates where passage in
PBMC may have resulted in a selection bias [10,12,21-31].
Detailed, longitudinal studies of C-HIV evolution from
chronic to advanced stages of infection in clinically well-
characterised ART-naïve patients are essential for under-
standing the importance of Env alterations in C-HIV patho-
genesis. Here, we utilized a large panel of functional HIV-1
Envs (n = 300) cloned directly from longitudinally-collected
plasma samples of 21 antiretroviral therapy (ART)-naïve
subjects from rural Zimbabwe, who experienced progres-
sion from chronic to advanced stages of C-HIV infection
over an approximately 3 year period [8]. In this cohort, only
one subject experienced a coreceptor switch whereby X4
strains emerged from antecedent R5 viruses at late stage in-
fection, with nearly all subjects (n = 20) harbouring only R5
viruses from chronic to advanced infection [8]. Thus, the
use of this longitudinal C-HIV Env panel offered a unique
opportunity to elucidate whether Env variants are selected
for during progressive C-HIV infection that exhibit altered
coreceptor engagement that is reflected in an increased
ability to utilise alternative coreceptors in vitro, and
whether particular patterns of alternative coreceptor en-
gagement are linked to the preference of the virus for
CCR5 or CXCR4.
Results and discussion
High frequency of alternative coreceptor usage by C-HIV
Envs from ART-naïve subjects who progressed from
chronic to advanced infection
Using a panel of 300 C-HIV Envs cloned from longitu-
dinal plasma samples of 21 ART-naïve subjects who ex-
perienced progression from chronic to advanced stages
of C-HIV infection over an approximately 3 year period,
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(n = 20) progressed whilst harbouring only R5 Env vari-
ants (n = 294 Envs), suggesting that R5 C-HIV strains
evolve in vivo in the absence of coreceptor switching
[8]. Moreover, a recent cross sectional study showed a
functional linkage between the use of CCR5 and the al-
ternative coreceptor FPRL1 that was unique to C-HIV
Envs, as well as less robust linkages between CCR5/
CCR3 usage and CCR5/CCR8 usage [10], suggesting an
altered use of CCR5 by C-HIV Envs that may manifest
as greater promiscuity for ability to use certain alterna-
tive coreceptors in vitro.
To determine the frequency of FPRL1-, CCR3- and
CCR8-usage by the R5 C-HIV Envs from our cohort, we
produced luciferase reporter viruses pseudotyped with
each of the 294 R5 Envs, and assessed their ability to enter
NP2-CD4 cells expressing either CCR5, FPRL1, CCR3 or
CCR8 (Figure 1). Consistent with the results of previous
studies [10,11], when analyzed as a group the R5 C-HIV
Envs used the alternative coreceptors less frequently than
CCR5 (p < 0.0001 by a Mann–Whitney U-test), and used
CCR3 and CCR8 less frequently than FPRL1 (p < 0.001 by
a Mann–Whitney U-test). However, 79.6% of the Envs
tested (n = 234) were able to use at least one of the alter-
native coreceptors for entry. Of these, 87.2% (n = 204)
used FPRL1, 54.7% (n = 128) used CCR3, 28.2% (n = 66)Figure 1 Alternative coreceptor usage by R5 C-HIV Envs.
Luciferase reporter viruses pseudotyped with each of the C-HIV R5
Envs (n = 294) were used to infect NP2-CD4 cells expressing CCR5,
FPRL1, CCR3 or CCR8, and the levels of HIV-1 entry were determined
as described in the Methods. The background level of luciferase
activity, as determined by infections with luciferase reporter virus
pseudotyped with the non-functional ΔKS Env [44], is shown by the
horizontal dashed line. The data shown are the means and standard
deviations of entry levels of all the R5 C-HIV Envs in the different cell
types, and are representative of 3 independent experiments, each
performed in triplicate. The individual dots represent mean entry
levels of triplicates from a representative experiment. Statistical
comparisons were made using a Mann–Whitney U test. P values < 0.05
were considered statistically significant.used CCR8, and 17.1% (n = 40) used all three alternative
coreceptors for entry. Notably, 5% of Envs (n = 14) used
FPRL1 more efficiently than CCR5. The R5 C-HIV Envs
that were negative for alternative coreceptor activity
remained negative when higher virus inoculums were used
(data not shown). This relatively broad usage of FPRL1,
CCR3 and CCR8, whilst concordant with a recent cross
sectional study of chronic C-HIV Envs [10], was not ob-
served in another study of C-HIV Envs cloned from re-
cently infected subjects which showed relatively frequent
usage of GPR15, CXCR6 and APJ for entry but relatively
infrequent usage of FPRL1, CCR3 and CCR8 [12]. To-
gether, these results suggest that usage of FPRL1, CCR3
and CCR8 may be a phenotype of R5 C-HIV Envs that de-
velops at chronic stages of infection, and raises the possi-
bility that the efficiency of in vitro FPRL1, CCR3 and
CCR8 usage may increase from chronic to late stages of
C-HIV infection.
R5 Envs that persist from chronic to advanced C-HIV
infection may have more efficient usage of CCR3 and
FPRL1 as alternative HIV-1 coreceptors
To determine whether there are functional linkages be-
tween the use of CCR5 and that of FPRL1, CCR3 and/or
CCR8 during progressive, untreated C-HIV infection,
and whether any such linkages are altered from chronic
to advanced stages of C-HIV infection, we next directly
compared the efficiency of all the R5 C-HIV Envs to
enter NP2-CD4 cells expressing CCR5, FPRL1, CCR3 or
CCR8 by correlative analysis. In order to produce robust
comparisons, we analyzed the entry levels from a com-
mon dilution of virus that resulted in luciferase signals
that were within the linear range of activity for each of
the cell types that were permissive for virus entry, as de-
scribed in the Methods.
The efficiency of the individual C-HIV Envs to use
FPRL1, CCR3 and CCR8 as alternative coreceptors for
HIV-1 entry, in comparison to their ability to use CCR5
and/or CXCR4, is shown in Additional file 1: Table S1. To
determine whether linkages existed between the ability of
the R5 Envs to use CCR5 and alternative coreceptors, we
first performed univariable clustered linear regression with
robust variance for all the Envs across the cohort, regard-
less of the disease stage. In these analyses, clustered re-
gression was used to account for the possible influence of
intra-subject Env similarities. Our results show statistically
significant positive correlations between the ability of the
R5 C-HIV Envs to use CCR5 and CCR3, FPRL1 and
CCR8 (Figure 2A and Table 1). To determine whether
these correlations altered during progression from chronic
to advanced infection, we next stratified the comparisons
according to whether the Envs were cloned from “enrol-
ment”, “intermediate” or “final” plasma samples [8], and
re-analyzed the data by univariable clustered linear
Figure 2 Associations between CCR5 usage and usage of CCR3, FPRL1 and CCR8 by R5 C-HIV Envs. Luciferase reporter viruses
pseudotyped with each of the C-HIV R5 Envs (n = 294) were used to infect NP2-CD4 cells expressing CCR5, FPRL1, CCR3 or CCR8, and the levels
of HIV-1 entry were determined as described in the Methods. Comparative entry levels for each of the individual Envs are shown in Additional file
1: Table S1. (A), scatterplots of all 294 R5 Envs comparing the levels of HIV-1 entry via CCR5 to that of CCR3 (left), FPRL1 (middle), and CCR8
(right). (B), these data were then stratified according to whether the Envs were cloned from the “enrolment” (top row), “intermediate” (middle
row) of “final” (bottom row) plasma samples from the longitudinal cohort [8]. Each dot represents the mean value of triplicate experiments.
Statistical analysis of these data is shown in Table 1.
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These results show statistically significant correlations be-
tween the ability of the R5 C-HIV Envs to use CCR5 and
CCR3, FPRL1 and CCR8 at all 3 timepoints, with the
exception of the CCR5/CCR3 correlation at the “intermedi-
ate” timepoint which neared statistical significance (p =
0.055). Of note, these longitudinal analyses showed near-
significant increases over time in the regression coefficients
(ie., the slopes of the best fit lines from the scatter plots) for
the correlations between CCR5/FPRL1 usage (β increases
from 0.232 to 0.336; p = 0.083) and CCR5/CCR3 usage (β
increases from 0.222 to 0.417; p = 0.091), but not CCR5/CCR8 usage (β remains unchanged; p = 0.993) (Table 1).
Although not quite reaching statistical significance, these
results suggest that R5 C-HIV Envs may evolve from
chronic to advanced infection to become better able to
utilize the alternative coreceptors FPRL1 and CCR3 for
HIV-1 entry. It is also possible that CCR5 usage by C-HIV
Envs becomes more efficient at late stage infection, which
may contribute also to increased FPRL1 and CCR3 usage.
Quantitative studies using the 293-Affinofile affinity profil-
ing system and mathematical modeling using VERSA (viral
entry receptor sensitivity analysis) metrics [32,33] are in
progress to determine if this is the case.
Table 1 Statistical analysis of correlations between CCR5 and alternative coreceptor usage
Correlation All Envs Enrolment Envs Intermediate Envs Final Envs
β 95% CI p-value β 95% CI p-value β 95% CI p-value β 95% CI p-value
CCR5/FPRL1 0.268 0.178, 0.359 <0.001 0.232 0.116, 0.347 <0.001 0.228 0.113, 0.343 0.001 0.336 0.196, 0.476 <0.001
CCR5/CCR3 0.284 0.148, 0.420 <0.001 0.222 0.029, 0.384 0.010 0.204 −0.005, 0.413 0.055 0.417 0.231, 0.604 <0.001
CCR5/CCR8 0.314 0.160, 0.467 <0.001 0.304 0.048, 0.561 0.023 0.366 0.185, 0.547 0.001 0.282 0.076, 0.488 0.010
Statistical analysis was conducted by univariable clustered linear regression with robust variance. P values < 0.05 were considered statistically significant.
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Envs appears to be constrained by the primary
coreceptor specificity
Although there is accumulating data on the patterns of
alternative coreceptor usage by R5 C-HIV Envs [10-12],
including our own data from the preceding studies, the
repertoire of alternative coreceptor usage by primary X4
C-HIV Envs is unknown. One of the 21 subjects from
our cohort (subject 1109) experienced a coreceptor
switch to X4 variants that were dominant in the “final”
plasma sample, which evolved over a ~3 year interval
from antecedent R5 viruses that were dominant in the
“enrolment” and “intermediate” plasma samples [8]. Sub-
ject 1109 affords an opportunity to examine the evolu-
tion of alternative coreceptor usage by C-HIV in the
context of primary coreceptor switching.
We therefore next compared the ability of the “enrol-
ment” R5 (n = 5), “intermediate” R5 (n = 4), and “final”
X4 (n = 6) Envs from subject 1109 to utilize CCR5, CXCR4,
FPRL1, CCR3 and CCR8 for HIV-1 entry. The efficiency
of these individual Envs to utilize the alternative cor-
eceptors in comparison to CCR5 and CXCR4 is shown in
Additional file 1: Table S1, and stratified according to dis-
ease stage in Figure 3. Our results show that the R5 “enrol-
ment” and “intermediate” Envs have very similar patterns
of alternative coreceptor usage, characterized by highly effi-
cient usage of FPRL1 and relatively inefficient usage of
CCR3 and CCR8. In contrast, the acquisition of CXCR4
usage by the “final” Envs in subject 1109 was accompanied
by a dramatic loss of ability to use FPRL1, a substantial in-
crease in ability to use CCR3, and no change in ability to
use CCR8. These studies demonstrate that in the C-HIV
variants from subject 1109, a striking inversion of specifi-
city for alternative coreceptors accompanied the switch in
primary coreceptor specificity from R5 to X4 phenotype.
Interestingly, in a longitudinal analysis of another subject
with C-HIV infection, transition from R5 to R5X4 pheno-
type did not result in loss of FPRL1 usage [11]. Together,
these studies further illustrate the functional link between
CCR5/FPRL1 usage.
Mechanistic insights into the linkage between CCR5 and
FPRL1 usage by C-HIV Envs
Whilst at a population level the preceding studies dem-
onstrate significant linkages between the usage of CCR5and alternative coreceptors by C-HIV Envs, the mechanistic
basis for these linkages is unknown. To better understand
the underlying Env determinants for these linkages, we
used a panel of Env mutants, which we used in our previ-
ous studies [8] to define the critical V3 loop changes in-
volved in reverting the X4 phenotype of 1109-F-30 Env to
R5X4 intermediates, and to a completely CCR5-restricted
phenotype. The amino acid sequences of the Env mutants
are shown in Figure 4, and their descriptions and primary
coreceptor specificities, which were determined in our re-
cent studies [8], are summarized in Figure 5B.
Luciferase reporter viruses pseudotyped with the Env
mutants (M1 through M15) or the unmodified X4 1109-F
-30 Env and R5 1109-E-10 Envs were characterized for
their ability to enter NP2-CD4/FPRL1 cells (Figure 5A);
we chose to conduct these studies in FPRL1-expressing
cells but not in CCR3- or CCR8-expressing cells, because
only FPRL1 was used by the R5 1109-E-10 Env and not by
the X4 1109-F-30 Env. Our results show that efficient use
of FPRL1 was restored to the 1109-F-30 Env by the M1,
M3, M7, M11, M12, M13, M14 and M15 mutations, but
was not restored by the M2, M4, M5, M6, M8, M9 or
M10 mutations (Figure 5A,B). These results indicate that
changing Arg318 in 1109-F-30 to Pro318, thus restoring
the “Gly317-Pro318-Gly319-Gln320” crown to the V3
loop (boxed in Figure 5C), either by itself or in combin-
ation with other mutations resulted in efficient FPRL1
usage. In contrast, all of the 1109-F-30 Env mutants which
did not use FPRL1 maintained the original Arg318 resi-
due. Together, these results suggest that the gp120 V3
crown is an important determinant for the maintenance of
efficient FPRL1 usage by C-HIV strains harbored by sub-
ject 1109, and that alteration of the “Gly317-Pro318-
Gly319” motif during the transition from R5 to X4 C-HIV
variants in this subject abruptly abolishes FPRL1 usage.
Using this panel of mutants we recently showed that
abolishing the Ile314-Gly315 insertion present in the X4
1109-F-30 Env (illustrated in Figure 5C), or changing
Arg318 to Pro318, resulted in acquisition of CCR5 usage
conferring an R5X4 phenotype, and that the presence of
both of these changes together abolished CXCR4 usage
altogether and conferred an R5 phenotype [8]. Here, we
show that just the Arg318 to Pro318 change that is
linked to CCR5 usage in this subject is critical for FPRL1
usage. Although limited to a single subject, these results
Figure 3 Changes in alternative coreceptor usage during the
transition from R5 to X4 phenotype in subject 1109. Luciferase
reporter viruses pseudotyped with “enrolment” (R5, n = 5), “intermediate”
(R5, n = 4) or “final” (X4, n = 6) Envs from subject 1109 [8] were used to
infect NP2-CD4 cells expressing CXCR4, CCR5, FPRL1, CCR3 or CCR8, and
the levels of HIV-1 entry were determined as described in the Methods.
The dotted lines indicate the limit of detection of coreceptor activity, as
determined by infections with luciferase reporter virus pseudotyped with
the non-functional ΔKS Env [44]. Comparative entry levels for each of the
individual Envs are shown in Additional file 1: Table S1. The data shown
are means and standard deviations of entry levels in the different cell
types, and are representative of 3 independent experiments, each
performed in triplicate. The individual circles represent mean entry levels
of each of the individual Env clones that were performed in triplicate,
from a representative experiment.
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CCR5 usage and FPRL1 usage by C-HIV Envs, which may
principally involve the V3 loop crown but not other V3 loopchanges associated with specificity for CCR5. Further studies
of C-HIV strains isolated from additional subjects are re-
quired to more precisely determine the significance of the V3
loop crown in mediating FPRL1 usage.
Conclusions
The mechanisms underlying the pathogenicity of C-HIV
strains remain to be determined by future studies, and in-
deed, with the establishment of our longitudinal C-HIV
Env panel we are now well positioned to learn more about
the Env determinants of C-HIV pathogenesis. The observa-
tion of unique functional linkages between the ability of R5
C-HIV Envs to use CCR5 and either CCR3, FPRL1 or
CCR8 as alternative coreceptors for HIV-1 entry shown
here and in previous studies [10] suggests unique selection
pressures imposed on C-HIV strains. Our longitudinal ana-
lysis of alternative coreceptor usage which suggests an im-
provement in the ability of R5 Envs to use CCR3 and
FPRL1 as alternative coreceptors at late stage infection, and
our mutagenesis studies which suggest a critical role for the
V3 loop crown in the functional linkage between CCR5/
FPRL1 usage, provide additional insights into how R5 C-
HIV Envs may evolve in vivo and contribute to C-HIV
pathogenesis. Since the V3 loop crown interacts with the
coreceptor ECLs, these findings suggest that R5 C-HIV
Envs may undergo adaptive alterations to acquire an altered
and/or more efficient interaction with the CCR5 ECL2 re-
gion (that is reflected also in an increased ability to engage
the alternative coreceptors), as has been shown recently to
occur with certain late-stage, macrophage tropic B-HIV
Envs [34]. This could serve to promote increased promis-
cuity of the Env for the utilization of alternative CCR5
conformations, as has been shown recently for certain
chronic C-HIV Envs in comparison to transmission/
founder C-HIV Envs [19,20]. Together, these observations
support the hypothesis that R5 C-HIV strains may evolve
in vivo via altered interactions with CCR5, which can




As we have stated previously [8], written informed con-
sent was provided by the subjects for the use of stored
plasma samples from which the Env clones used here
were derived . Ethics approval for the use of these sam-
ples was granted by the Medical Research Council of
Zimbabwe (MRCZ/A/918) and by the Central Medical
Scientific Ethics Committee of Denmark (624-01-0031).
Cells
NP2-CD4 cells stably expressing either CCR5, CXCR4,
CCR3, CCR8 or FPRL1 were maintained as described
previously [35].
Figure 4 C-HIV Env mutants. Amino acid sequences of the Env mutants, aligned against the gp120 sequence of the X4 1109-F-30 sequence.
The sequences and descriptions of these Env mutants have been reported previously [8], and are included again here to assist in the
interpretation of the functional data. Dots indicate residues identical to 1109-F-30, dashes indicate gaps. Numbers refer to amino acid positions in
the V1 and V3 loop regions. Descriptions of the Env mutants are provided in greater detail in the Methods.
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The Envs used in this study are expressed from the
pSVIII-Env mammalian expression plasmid [36], and
have been described in detail recently [8]. The Envs have
been assigned GenBank accession numbers HQ707833
to HQ708154. The clinical details of the study subjects
are also described in detail in Jakobsen et al [8]. Briefly,
Envs were cloned directly from plasma of 21 ART-naïve
individuals who progressed from chronic to advanced
stages of C-HIV infection, as determined by significant
declines in CD4+ T-cell count, over an approximately 3-
year period. Stored plasma samples that were collected
at study enrolment (“E”), approximately 1 year later (“I”,
representing the “intermediate” sample), and approxi-
mately 3 years after enrolment (“F”, representing the
“final” sample that was collected after CD4+ T-cell de-
cline) were used for Env cloning. Between 2 and 8 func-
tional and genotypically unique Envs from each plasma
sample, totalling 300 Envs across the cohort, were iden-
tified based on the ability to support the entry of Env-
pseudotyped GFP reporter viruses into JC53 cells [37].
The nomenclature of the Envs follows the “patient-sam-
ple-clone number” order. For example, Env clone “1109-
F-30” is clone number 30 from the final plasma sample
of subject 1109.
Production of Env-pseudotyped luciferase reporter viruses
Env-pseudotyped, luciferase reporter viruses were produced
by transfection of 293 T cells with pCMVΔP1ΔenvpA,
pHIV-1Luc and pSVIII-Env plasmids at a ratio of 1:3:1
using Lipofectamine 2000 (Invitrogen), as described previ-
ously [34,38-43]. Supernatants were harvested 48 h later,
clarified by filtration through 0.45 μM filters, aliquotted
and stored at −80°C.HIV-1 entry assays
The ability of Env-pseudotyped luciferase reporter viruses
to use CCR5, CXCR4, or the alternative coreceptors CCR3,
CCR8 and FPRL1 was determined by single-round entry
assays using NP2-CD4 cells stably expressing either
coreceptor. Briefly, 1 × 104 cells were inoculated with 5-
fold dilutions of each virus preparation for 6-hours at 37°C.
Cells were then media changed and incubated for 48-hours
at 37°C. Virus entry was then measured by assaying lucifer-
ase activity in cell lysates (Promega), according to the man-
ufacturers’ protocol. Usage of a particular coreceptor by a
given virus was determined to be positive if it yielded a ti-
tratable luciferase signal above background. For correlative
analyses of CCR5/alternative coreceptor usage, entry levels
from a common dilution of virus that resulted in luciferase
signals within the linear range of activity for each of the cell
types that were positive for virus entry were analyzed. In
most cases this was a 1:5 dilution. For viruses that used
only CCR5, data from a 1:5 dilution was similarly selected
for analysis provided this dilution resulted in linear-range
luciferase signals. For cell types yielding no detectable entry
for a given virus, background luciferase signals from the
same dilution that yielded linear range luciferase signals in
the respective permissive cell populations were used for
analysis. The negative controls used to determine the back-
ground level of luciferase activity included mock-infected
cells treated with culture medium instead of virus, and cells
inoculated with luciferase reporter virus pseudotyped with
the non-functional ΔKS Env [44].
Env mutants
All gp120 mutants were synthesized by GenScript Pty.
Ltd. (Piscataway, NJ, USA), and subcloned into the
pSVIII-Env expression vector [8]. The authenticity of the
Figure 5 V3 loop alterations important for the association between CCR5 and FPRL usage. (A), luciferase reporter viruses pseudotyped
with Env mutants (M1 through M15), or unmodified 1109-E-10 and 1109-F-30 Envs were used to infect NP2-CD4/FPRL1 cells, and the levels of
HIV-1 entry were determined as described in the Methods. Open bars indicate Envs where no detectable FPRL1 usage was observed, and shaded
bars indicate Envs with detectable FPRL1 usage. The dotted line indicates the limit of detection of coreceptor activity, as determined by
infections with luciferase reporter virus pseudotyped with the non-functional ΔKS Env [44]. The results shown are a compilation of 3 independent
experiments, each performed in triplicate. The data shown are means, and the error bars represent standard errors of the means. (B), summary of
descriptions of the Env mutants. Shaded rows illustrate the Env mutants which had detectable FPRL1 usage. The R318P mutation, which was
strongly associated with both CCR5 and FPRL1 usage, is highlighted in bold. The primary coreceptor specificity of the Env mutants (ie., whether
they exhibit an R5, R5X4 or X4 phenotype) was determined previously [8]. (C), comparisons of the V3 loop region between the R5 1109-E-10 and
X4 1109-F-30 Envs. Shown in bold are the amino acids tested by mutagenesis for modulation of FPRL1 usage, and boxed is the V3 crown motif
shown to principally modulate FPRL1 usage.
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This series of mutants involved replacing various motifs
of the X4 1109-F-30 Env with those of the antecedent
R5 1109-E-30 Env from subject 1109. The amino acid
sequences of the V1 and V3 loops of these 2 Envs, where
the distinguishing amino acid changes were located, and
the consequent amino acid sequences of the various
1109-F-30 Env mutants are shown in Figure 4. The Env
mutants consist of the 1109-F-30 Env with Pro318 of
the 1109-E-10 Env (M1), 1109-F-30 with deletion of the
Ile314-Gly315 insertion (M2), 1109-F-30 with Pro318 of
the 1109-E-10 Env and deletion of the Ile314-Gly315 in-
sertion (M3), 1109-F-30 with Thr329 of 1109-E-10 (M4),
1109-F-30 with Asn331 of 1109-E-10 (M5), 1109-F-30
with the whole V1 loop of 1109-E-10 (M6), 1109-F-30
with the V1 loop and Pro318 of 1109-E-10 (M7), 1109-F
-30 with the V1 loop of 1109-E-10 and deletion of the
Ile314-Gly315 insertion (M8), 1109-F-30 with the V1
loop and Thr329 of 1109-E10 (M9), 1109-F-30 with the
V1 loop and Asn331 of 1109-E-10 (M10), 1109-F-30
with the V1 loop and Pro318 of 1109-E-10 and deletion
of the Ile314-Gly315 insertion (M11), 1109-F-30 with
the V1 loop, Pro318 and Thr329 of 1109-E-10 (M12),
and 1109-F-30 with the V1 loop, Pro318 and Asn331 of
1109-E-10 (M13). In addition, we produced an Env mu-
tant of 1109-F-30 containing the whole V3 loop of 1109-
E-10 (M14), and a mutant of 1109-F-30 containing both
the V3 and V1 loops of 1109-E-10 (M15).
Additional file
Additional file 1: Table S1. Alternative coreceptor usage of Env clones.
The Level of virus entry in NP2-CD4 cells expressing CCR3, FPRL1 or CCR8 or
was scored as – (<5 fold above background), + (5-50 fold above
background), ++ (50-300 fold above background), or +++ (>300 fold above
background). The results for virus entry into NP2-CD4 cells expressing CCR5
or CXCR4, using equivalent infectious units of virus inoculum, are shown
alongside these data for comparison. E, I and F refer to Envs cloned from
plasma obtained at study enrolment, approximately 1 year later
(intermediate), and approximately 3 years after enrolment (Final),
respectively (Jakobsen et al., [8]).
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